FUNDAMENTALS · Fundamentals · JP Healthcare

CYBERDYNE (7779) Fundamentals 2026 — P/E 308.3x, Revenue Analysis | SniperIQ

CYBERDYNE (7779) is a JP-listed Healthcare company in Medical - Devices with a market capitalization of ¥29.6B, trading at ¥222.00 on the JPX. This SniperIQ fundamentals page covers CYBERDYNE's valuation (P/E 308.3x, P/B 1.2x), profitability (net margin 4.0%), revenue (¥3.8B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥29.6B
P/E (TTM)308.3x
Net Margin4.0%
Revenue (FY26)¥3.8B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is CYBERDYNE's market cap?

CYBERDYNE (7779) has a market capitalization of approximately ¥29.6B, trading at ¥222.00 on the JPX. Market cap moves with the live share price.

What is CYBERDYNE's P/E ratio?

CYBERDYNE's trailing twelve-month P/E ratio is 308.3x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is CYBERDYNE?

CYBERDYNE runs a net profit margin of 4.0%, a gross margin of 46.9%, and an operating margin of -28.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does CYBERDYNE generate?

CYBERDYNE reported revenue of ¥3.8B for fiscal year 2026, with net income of ¥153M and earnings per share (EPS) of 0.72. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does CYBERDYNE pay a dividend?

CYBERDYNE does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is CYBERDYNE financially healthy?

CYBERDYNE carries a debt-to-equity ratio of 0.01x and a current ratio of 14.31x, with a market beta of 0.84. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is CYBERDYNE a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CYBERDYNE (7779) the key facts are: market cap ¥29.6B, P/E 308.3x, revenue ¥3.8B, 52-week range 164-420. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track CYBERDYNE's full fundamentals live

Get CYBERDYNE's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Biogen (BIIB) fundamentals · Thyrocare Technologies (THYROCARE) fundamentals · China Medical System Holdings (0867) fundamentals · Illumina (ILMN) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons